$KOD News

Chardan Capital Upgrades Kodiak Sciences to Buy, Raises Price Target to $61

A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda

Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

Kodiak Sciences Q1 EPS $(0.94) Misses $(0.92) Estimate

Kodiak Sciences' KSI-101 MESI Data From Tertiary Care Uveitis Practice Consistent With Phase 1b APEX Study Results

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Eagle Eye Solutions Group Leads The Charge In UK Penny Stocks

Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)

Kodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In Focus

Assessing Kodiak Sciences (KOD) Valuation After Recent Share Price Momentum And Conflicting Signals

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Kodiak Sciences Q4 EPS $(1.04) Misses $(1.00) Estimate

Kodiak Sciences (KOD) Is Up 66.3% After Strong Zenkuda GLOW2 Phase 3 Data - Has The Bull Case Changed?

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

KOD stock has given up its prior gain. Kodiak Sciences shares were trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and raised its price target from $38 to $58.

KOD stock has given up its prior gain. Kodiak Sciences shares were trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and raised its price target from $38 to $58.

How Kodiak Sciences Stock Rises To $120?

Kodiak Sciences: Shares Up On Positive Eye Disease Data - But I Remain On Sidelines